MalariaWorld summer edition
Between half July and half August we will provide you with our shortened summer edition. The overview of scientific articles will remain the same, but there will be less other news and fewer announcements. If you need to get in touch with us or if you want to advertise a vacancy or event, please click here to contact us.
Stay healthy, stay safe and enjoy MalariaWorld
Founder & Senior Editor MalariaWorld
Director Dutch Malaria Foundation
Watch below the recording of the Masterclass "Vectors Asia, Africa & the Americas" with S. Manguin, I. Vythilingam, Y. Rubio Palis, L. Koekemoer
Ifakara MasterClasses in Public Health & Medical Entomology. Episode XXVIII: Thursday, July 8th 2021
New report spells out double dividend for accelerating ending malaria and advancing gender equality. As patients, caregivers and providers, women and adolescent girls in malaria-endemic countries are leading investors in the malaria fight, yet systemic gender inequalities also cause them to bear the societal, health and economic burdens of the disease.
Mutaz Akkawi, Pascal Gisenya, Jérôme Munyangi, Pierre Lutgen
…or the key of malaria transmission.
Already 25 years ago it was known that malaria pigment (hemozoin, Hz, biocrystallized heme) is not an inert material. Crude pigment, as present in infected erythrocytes and shed after schizont rupture, may be considered the 'natural diet' ingested by macrophages in infected blood. Hemozoin is a powerful source of radicals, necrosis factor-alpha, interleukins 1 and 6.
Sanaria® PfSPZ-CVac vaccine protected 100% of six subjects against a genetically distant variant parasite strain for 3 months, the first time that such complete protection has ever been achieved for such a long period. Results set the scene for development of a traveler’s vaccine, seasonal malaria vaccinations and genetically attenuated parasites that do not fully develop in the liver through to early blood stage.
Watch below the recording of the Masterclass "Malaria Maps and Models" with Profs. S. Bhatt, S. Kiware, L. Tusting & J. Gerardin
Ifakara MasterClasses in Public Health Research & Practice. Episode XXVII: Thursday, July 1st 2021
Findings published in Nature offer potential for use by travelers and prevention of malaria in African populations in near future
ROCKVILLE, MD, USA – June 30, 2021 – Researchers from Sanaria® Inc. and the National Institutes of Health (NIH) are making progress in the development of highly protective malaria vaccines.
In an article published today in Nature, Sanaria’s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company’s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.
The Malaria Eradication Scientific Alliance (MESA) is seeking volunteers as MESA Correspondents to report from the online MESA Webinars: Science for Malaria Impact. The webinars will be held every first Wednesday of the month starting in May until December and will last 1h starting at 2:00 pm CEST.
The third session of our monthly MESA Webinars: Science for Malaria Impact will be held on July 7 at 2 PM CAT (8 AM EDT, 8 PM SGT). Focusing on genomics, the third webinar will feature Christian Happi, Professor of Molecular Biology and Genomics and Director of the World Bank funded African Center of Excellence for Genomics of Infectious Diseases (ACEGID), in Redeemer’s University, Nigeria, and Stella Chenet Carrasco, Professor at the National University Toribio Rodríguez de Mendoza (UNTRM), Peru.
Watch below the recording of the Masterclass "Two Billion Mosquito Nets & Counting" with Prof. Christian Lengeler from Swiss TPH.
Ifakara MasterClasses in Public Health Research & Practice. Edition XXVI: Thursday, June 24th 2021
Mutaz Akkawi, Jerome Munyangi, Pierre Lutgen
Already 200 years ago malaria pigment, later called hemozoin, was discovered.
Virchow, R. Zur pathologischen Physiologie des Bluts. Archiv f. pathol. Anat. 1, 547–563 (1847). https://doi.org/10.1007/BF02114475
COVID-19 has placed a strain on health systems globally. Last March 2020, APMEN held a session at an early stage in the pandemic, where we explored how countries in the Asia Pacific region were going about sustaining malaria services despite the nascent health crisis of COVID-19. A year on, as we are still very much dealing with the pandemic and rolling out the vaccine progressively, we take stock on the region’s ongoing challenges and successes in keeping malaria under check.
Watch below the recording of the MESA webinar "New Approaches to Improve Malaria Mosquito Surveillance and Control", featuring Fredros Okumu, director of science at the Ifakara Health Institute (IHI) in Tanzania, and Mercy Opiyo, medical entomologist at the Manhiça Health Research Centre (CISM) in Mozambique and the Barcelona Institute for Global Health (ISGlobal) in Spain.
ROCKVILLE, MD, USA - June 8, 2021 - The PfSPZ malaria vaccines of Sanaria Inc. are unique in vaccine development as they are composed of weakened (attenuated) forms of the live parasite cells that cause malaria. These parasite cells are called eukaryotic cells and there are no vaccines against any infectious disease composed of such cells. Furthermore, there are no licensed vaccines against any infectious disease caused by a eukaryotic pathogen.
World Health Organization, 28 May 2021
The World Health Assembly, the main governing body of the World Health Organization, has adopted a new resolution that aims to revitalize and accelerate efforts to end malaria, a preventable and treatable disease that continues to claim more than 400 000 lives annually.
Watch below the recording of the MasterClass "The Enduring Search for Malaria Vaccines" with Sanaria's Chief Executive and Scientific Officer Prof Stephen Hoffman.
Ifakara MasterClasses in Public Health Research & Practice. Episode XXV: Thursday, June 3rd 2021.
The remarkable discovery of considerable plasmodial life cycle activity in the human spleen has been reported [1,2]. There is also recent non-microscopic evidence suggestive of malaria parasite accumulation there .
The idea that the non-circulating parasite origin of Plasmodium vivax malarial recurrence is both hypnozoites [1,2] and merozoites (not hypnozoites only) dates from 2011 [3,4]. The history appears in Table 1 in . There is recent (and superb) evidence that my decade-old, bimodal recurrence hypothesis must be correct.
The second session of the monthly MESA Webinars: Science for Malaria Impact will be held on June 10 at 2 PM CAT (8 AM EDT, 8 PM SGT). Focusing on entomology, it will feature Fredros Okumu, director of science at the Ifakara Health Institute (IHI) in Tanzania, and Mercy Opiyo, medical entomologist at the Manhiça Health Research Centre (CISM) in Mozambique and the Barcelona Institute for Global Health (ISGlobal) in Spain.
Deadline: 30 May 2021 at 17:00
It is the intent of this RFP to secure competitive proposals from capable vendors to carry out the supply of personal protective equipment and other implementation materials to Malaria Consortium Nigeria.
Sanaria is a biotechnology company developing vaccines protective against malaria. Sanaria’s vaccines have proven highly protective against Plasmodium falciparum infection in humans. Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
The Malaria Eradication Scientific Alliance (MESA) is seeking three volunteers as MESA Correspondents to report from the EMBL Conference BioMalPar XVII - Biology and Pathology of the Malaria Parasite to be held virtually on May 25 - 27, 2021.
Innovator Awards are open to researchers who are developing healthcare innovations that could have a major and measurable impact on human health. Individuals and teams from not-for-profit organisations can apply. Organisations can be based anywhere in the world (apart from mainland China). Funded organisations must sign up to the Wellcome grant conditions. You can work in any scientific discipline, including a discipline outside life sciences.
The Global Malaria Programme is seeking public comments on the following preferred product characteristics (PPC) on indoor residual spraying products for malaria transmission control in areas with insecticide-resistant mosquito populations.
Interested parties may provide their comments to email@example.com by 15 May 2021.
For the draft for consultation see attached pdf.
Many countries in the Asia-Pacific region have achieved impressive reductions in malaria burden, but persistent residual malaria caused in large part by outdoor-biting vectors pose a serious challenge to malaria elimination objectives. Repellent methods to reduce vector contact with humans offer a tantalizing approach to reduce transmission, and several different methods varying from topical applications, impregnated clothing, space-repellents and others have been tested.
Protect vulnerable children against malaria
We are thrilled to announce our new exciting partnership project "Printed mosquito nets for Uganda"!
For the first time, MESA will virtually celebrate a series of monthly discussions, the MESA Webinars: Science for Malaria Impact. These webinars bring together the malaria community of innovators and showcase the work of malaria-endemic researchers. Starting in May, the virtual events will be held on the first Wednesday of each month and will feature two researchers. These one-hour sessions will cover a range of topics, from social sciences to entomology, through insecticide drug resistance, stratification and genomics.
When: First Wednesday of each month until December
Time: 8:00 am EDT - 2:00 pm CEST/CAT - 8:00 pm SGT
Since 2017, WHO has supported a group of 21 malaria-eliminating countries through a special initiative called the “E-2020”. This report charts their progress towards a common goal: eliminating malaria within the 2020 timeline. According to this report, 8 E-2020 member countries reported zero indigenous cases of malaria in 2020, a remarkable achievement in view of the ongoing global COVID-19 pandemic. Maintaining zero cases is a testament to their commitment to protect hard-won gains and keep the disease at bay.
For the pdf of the report see attachment.
It [25 April] is World Malaria Day 2021 and we call on all stakeholders to draw the line against this disease, because all malaria cases and deaths are preventable. Although the WHO African Region accounts for virtually all 94% of global malaria cases and deaths, our countries have made progress in preventing both.
Waging a malaria elimination campaign without community support is like fighting a battle with one arm tied behind your back. We need the people who bear the brunt of malaria to understand what elimination program objectives are, and gain their help to identify, deliver and assess solutions likely to achieve these objectives.